Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Praxis Precision Medicines stock in Canada

Own Praxis Precision Medicines shares in just a few minutes.

Praxis Precision Medicines is a biotechnology business based in the US. Praxis Precision Medicines stocks (PRAX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.8 – a decrease of 7.01% over the previous week. Praxis Precision Medicines employs 67 staff and has a market cap (total outstanding stock value) of $751.8 million.

How to buy shares in Praxis Precision Medicines

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PRAX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Praxis Precision Medicines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Praxis Precision Medicines stock price (NASDAQ: PRAX)

Use our graph to track the performance of PRAX stocks over time.

Praxis Precision Medicines shares at a glance

Information last updated 2021-11-28.
Latest market close$17.11
52-week range$12.71 - $60.95
50-day moving average $20.04
200-day moving average $24.07
Wall St. target price$36.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.47

Compare online trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
OFFER
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Praxis Precision Medicines price performance over time

Historical closes compared with the close of $17.11 from 2021-11-30

1 week (2021-11-24) -7.01%
1 month (2021-11-01) -21.26%
3 months (2021-09-01) -13.15%
6 months (2021-06-01) -13.32%
1 year (2020-12-01) -59.44%
2 years (2019-11-27) N/A
3 years (2018-11-27) N/A
5 years (2016-11-27) N/A

Praxis Precision Medicines financials

Gross profit TTM $0
Return on assets TTM -37.84%
Return on equity TTM -66.28%
Profit margin 0%
Book value $6.67
Market capitalisation $751.8 million

TTM: trailing 12 months

Praxis Precision Medicines share dividends

We're not expecting Praxis Precision Medicines to pay a dividend over the next 12 months.

Praxis Precision Medicines overview

Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc. ; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. ; and collaboration with The Florey Institute to develop three novel ASOs.

Stocks similar to Praxis Precision Medicines

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site